Adam M. Willis, LtCol, MD, PhD

Adam M. Willis, LtCol, MD, PhD, serves as a senior technical acquisition lead within the Defense Advanced Research Projects Agency (DARPA), driving the procurement of high-risk, high-reward biotechnology research and development programs. In this capacity, he orchestrates the solicitation, evaluation, and award of contracts aligned with DARPA’s mission to accelerate transformative military capabilities through cutting-edge life sciences innovation. His acquisitions primarily focus on early-stage R&D in bio-integrated systems, neurotechnology, and advanced therapeutic platforms, often supporting proof-of-concept and transition-ready prototypes under flexible, milestone-driven contracting mechanisms such as Other Transaction Authorities and Phase I/II SBIRs. Willis maintains strategic partnerships with leading biomedical and defense technology firms, including Abbott Laboratories Inc., Systems & Technology Research LLC, and AMD International Technologies LLC. These relationships are characterized by deep technical collaboration, rapid iteration cycles, and a focus on dual-use innovations with both military and civilian applications. He frequently engages with organizations possessing specialized expertise in molecular diagnostics, synthetic biology, and bioelectronic interfaces, fostering agile, non-traditional vendor relationships that prioritize scientific breakthrough over conventional commercial delivery models. His procurement portfolio reflects a strict focus on unrestricted competition, with 100% of awards issued under no set-aside classifications. This approach underscores a mission-driven preference for selecting the most technically capable entities regardless of size or socioeconomic status, prioritizing innovation velocity and technical excellence over socioeconomic compliance metrics. The primary NAICS classification guiding his acquisitions is 541714—Research and Development in Biotechnology—reflecting an exclusive emphasis on advanced biological engineering, gene editing platforms, bio-sensing systems, and human-machine integration technologies. Willis’s work centers on enabling next-generation medical countermeasures, autonomous biological diagnostics, and adaptive physiological monitoring systems critical to future warfighter readiness.